Celcuity (CELC) – Globe Newswire
-
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
-
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
-
Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
-
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
-
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
-
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
-
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
-
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
-
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
-
Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call
-
Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
-
Celcuity to Host Virtual Science Day for Investors
-
Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial
-
Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer
-
Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
-
Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call
-
Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023
Back to CELC Stock Lookup